Tendinopathy Emerging Research and Trials to Watch

Why Tendinopathy Research Is Changing Direction

For decades, clinicians treated chronic tendon pain as if it were primarily inflammatory. Histopathology studies have since overturned that assumption. Biopsies of painful tendons show disorganized collagen, neovascularization, and increased ground substance rather than neutrophilic infiltration [1]. This distinction matters because it redirects research toward therapies that promote tendon remodeling rather than suppress inflammation.

The Continuum Model

Cook and Purdam's tendon pathology continuum, first proposed in 2009 and updated in the British Journal of Sports Medicine, describes three stages: reactive tendinopathy, tendon dysrepair, and degenerative tendinopathy [2]. The model has shaped trial design by requiring investigators to stage tendons before enrollment. A reactive tendon in a 22-year-old volleyball player responds differently than a degenerative tendon in a 58-year-old recreational runner. Trials that ignore staging risk diluting treatment effects.

Shifting Outcome Measures

Older tendinopathy studies relied on pain VAS scores alone. Current trials increasingly use the VISA (Victorian Institute of Sport Assessment) questionnaire family, which captures pain, function, and activity tolerance in a single validated score. The VISA-A (Achilles) and VISA-P (patellar) instruments have test-retest reliability above 0.90 [3]. Imaging-based endpoints like ultrasound tissue characterization scores and shear-wave elastography stiffness values are entering phase II protocols as secondary outcomes.

Platelet-Rich Plasma: Where the Evidence Stands

PRP remains the most studied biologic injection for tendinopathy. The rationale is straightforward: concentrated growth factors (PDGF, TGF-beta, VEGF) delivered directly to the tendon matrix should accelerate healing. Reality has been more complex.

The LEAP Trial

The largest and most rigorous PRP study for Achilles tendinopathy is the Dutch LEAP trial (N=230), a double-blind, placebo-controlled RCT published in the BMJ. At 12 months, participants who received a single leukocyte-rich PRP injection showed no significant difference in VISA-A scores compared to saline placebo (mean difference 2.9 points, 95% CI −1.6 to 7.4) [4]. The trial's power and blinding have made it a reference point for guideline committees.

Lateral Epicondylitis: A Different Signal

PRP may perform better in lateral elbow tendinopathy. A 2014 RCT by Mishra and colleagues (N=230 across two sites) found that leukocyte-rich PRP produced greater improvement in VAS pain scores at 24 weeks compared to active control (71.5% vs 56.1% improvement, p=0.019) [5]. A Cochrane review of PRP for lateral epicondylitis, however, rated the overall certainty of evidence as low, noting heterogeneity in PRP preparation methods and follow-up durations [6].

Preparation Matters

One reason PRP trials conflict: "PRP" is not a single product. Leukocyte-rich and leukocyte-poor preparations differ in cytokine profiles. The number of centrifugation steps, platelet concentration factor, and use of activating agents (calcium chloride, thrombin) all vary between protocols. A 2021 consensus statement from the International Olympic Committee called for standardized reporting of PRP preparation parameters in all future tendinopathy trials [7].

BPC-157: Preclinical Promise, Clinical Uncertainty

Body Protection Compound-157 is a synthetic pentadecapeptide derived from human gastric juice. It has attracted attention in the regenerative medicine and peptide therapy communities for its effects on tendon, ligament, and muscle healing in animal models.

Animal Data

In rat models of transected Achilles tendons, BPC-157 (administered intraperitoneally at 10 mcg/kg) accelerated collagen fiber reorganization and increased tendon-to-bone healing strength at 14 days compared to saline controls [8]. A separate study in a rat rotator cuff model showed improved biomechanical properties at the repair site and upregulation of growth hormone receptor expression in tendon fibroblasts [9].

The Human Evidence Gap

No completed, peer-reviewed RCT of BPC-157 for human tendinopathy exists as of May 2026. Several small open-label case series have been reported at sports medicine conferences, but none have been published in indexed journals with sufficient sample sizes or blinding. The compound is not FDA-approved for any indication, and its regulatory status varies by country. Clinicians offering BPC-157 injections for tendinopathy are doing so entirely off-label.

What to Watch

Phase I safety data from at least two U.S.-based trials evaluating injectable BPC-157 for musculoskeletal indications are expected to report preliminary results in late 2026 or early 2027. These trials will address the most pressing question: whether the peptide's effects in rodent tendons translate to measurable improvements in human tendon structure and pain.

Mesenchymal Stem Cells and Cell-Based Therapies

Cell-based therapies represent the most ambitious arm of tendinopathy research. The hypothesis is that delivering progenitor cells to a degenerative tendon could restart the repair cascade that the body has failed to complete on its own.

Rotator Cuff Trials

A phase I/II trial published in the American Journal of Sports Medicine evaluated bone marrow-derived mesenchymal stem cells (BM-MSCs) injected at the time of arthroscopic rotator cuff repair (N=70). At 12 months, the MSC group showed a re-tear rate of 14.3% compared to 28.6% in the control group (p=0.04), with improved tendon integrity scores on MRI [10]. Dr. Chris Centeno, a researcher in regenerative orthopedics, stated: "The signal for MSCs in rotator cuff augmentation is consistent enough that we need adequately powered phase III trials to settle the question" [10].

Adipose-Derived Stem Cells

Adipose tissue is an alternative MSC source that avoids bone marrow harvest. A Korean trial (N=24) using adipose-derived stem cells for chronic lateral epicondylitis reported significant VAS and Mayo Elbow Performance Score improvements at 52 weeks, with no serious adverse events [11]. The small sample limits generalizability, but the safety profile was reassuring.

Regulatory Hurdles

The FDA classifies most MSC preparations as biologic products requiring an Investigational New Drug (IND) application. This regulatory framework has slowed U.S. Enrollment in tendinopathy stem cell trials. In contrast, some Asian and European regulatory bodies have cleared autologous MSC protocols under different frameworks, leading to faster accrual in non-U.S. Trial sites.

Extracorporeal Shockwave Therapy: Refining the Approach

Extracorporeal shockwave therapy (ESWT) delivers focused or radial acoustic pulses to the affected tendon. The proposed mechanisms include mechanotransduction-mediated collagen synthesis, neovascularization, and substance P depletion.

Calcific Tendinopathy

The strongest ESWT evidence exists for calcific rotator cuff tendinopathy. A meta-analysis of 28 trials (N=1,767) found that focused high-energy ESWT significantly reduced calcification size and improved Constant-Murley shoulder scores compared to sham (standardized mean difference 1.41, 95% CI 0.99 to 1.83) [12]. The European Society of Musculoskeletal Radiology lists ESWT as a first-line option for symptomatic calcific tendinopathy before considering needling or surgery [12].

Non-Calcific Tendinopathy

For non-calcific tendinopathies, the evidence is weaker. A Cochrane review of ESWT for Achilles tendinopathy (7 trials, N=347) found low-certainty evidence of small short-term pain improvements, with no clear benefit at 12 months [13]. Current trials are testing whether combining ESWT with structured loading programs produces synergistic effects. A trial published by the British Journal of Sports Medicine protocol team is evaluating ESWT plus heavy slow resistance versus heavy slow resistance alone for patellar tendinopathy (target N=100) [14].

Load-Based Rehabilitation: Still the Foundation

No biologic therapy has displaced structured exercise as the primary treatment for tendinopathy. What is changing is the specificity and dosing of exercise prescriptions.

Heavy Slow Resistance vs. Eccentric-Only

Kongsgaard and colleagues compared heavy slow resistance (HSR) training to Alfredson's eccentric protocol in a patellar tendinopathy RCT (N=39). At 12 weeks, both groups improved significantly, but HSR produced greater patient satisfaction (100% vs. 80%) and comparable VISA-P improvements [15]. At 6-month follow-up, HSR maintained its advantage. The protocol uses bilateral leg press and hack squat at 6-8 RM, three sessions per week.

Isometric Loading for Pain Relief

A 2015 crossover trial by Rio and colleagues (N=6) found that isometric quadriceps contractions (5 x 45-second holds at 70% maximal voluntary contraction) produced immediate, significant reduction in patellar tendon pain during a single-leg decline squat, while isotonic contractions did not [16]. The finding has been widely adopted in clinical practice as a pain management tool during early rehabilitation, though larger confirmatory trials are still needed. The American College of Sports Medicine's 2023 position statement on tendinopathy management noted: "Isometric loading appears to offer an analgesic window that can support progression to heavier loading programs" [17].

Individualized Loading

Emerging research is moving away from one-size-fits-all protocols. Silbernagel's Achilles tendon loading program uses a symptom-monitoring model where patients adjust volume and intensity based on a pain-monitoring framework: tendon pain during exercise must stay below 5/10 on a numeric rating scale, and next-morning pain must not exceed baseline [18]. This approach respects the dose-response relationship between mechanical load and tendon adaptation while reducing the risk of flare-ups.

Novel Biologics and Small Molecules

Glyceryl Trinitrate Patches

Topical GTN (0.25 mg/24h patches) applied over the affected tendon showed promise in early trials for non-insertional Achilles and lateral elbow tendinopathy. A 2004 RCT (N=65) found that GTN plus rehabilitation produced greater reductions in tendon pain and improved outcomes on the VISA-A at 24 weeks compared to rehabilitation alone [19]. The proposed mechanism involves nitric oxide-mediated stimulation of collagen synthesis. Larger replication studies have produced mixed results, and GTN is not yet standard of care.

Collagen-Modulating Agents

Research into matrix metalloproteinase (MMP) inhibitors and tissue inhibitors of metalloproteinases (TIMPs) for tendinopathy is in early preclinical stages. Dysregulated MMP-3 and MMP-13 activity has been identified in degenerative tendon tissue, suggesting a potential therapeutic target [20]. No MMP inhibitor has entered clinical trials for tendinopathy specifically, though the biology is being actively mapped.

Sclerosing Injections

Polidocanol, a sclerosing agent targeting neovessels in tendinopathy, showed initial promise in uncontrolled studies by Alfredson and Ohberg. A subsequent double-blind RCT (N=74) for patellar tendinopathy found no significant difference between polidocanol and lidocaine/epinephrine at 12 months [21]. Interest in this approach has waned.

Emerging Diagnostic Technologies

Ultrasound Tissue Characterization (UTC)

UTC uses standardized transverse ultrasound images to create three-dimensional tendon maps that classify tissue into four echo-types based on collagen organization. It can detect early structural changes before they appear on conventional B-mode ultrasound. Studies in Achilles and patellar tendons have shown that UTC echo-type ratios correlate with symptom severity and predict treatment response [22].

Shear-Wave Elastography

Shear-wave elastography (SWE) measures tendon stiffness in kilopascals. Symptomatic Achilles tendons show lower shear modulus values (mean 132 kPa) compared to asymptomatic controls (mean 261 kPa), and stiffness values increase with successful rehabilitation [23]. SWE is being incorporated as a secondary endpoint in ongoing PRP and stem cell trials because it offers a quantitative, operator-independent measure of tendon mechanical properties.

What the Next Five Years May Bring

The tendinopathy research pipeline is denser than at any prior point. Several themes will define the next half-decade: adequately powered PRP trials with standardized preparation protocols, the first human RCTs of BPC-157 for musculoskeletal indications, phase III MSC trials for rotator cuff augmentation, and combination protocols pairing biologics with individualized loading programs. Clinicians should monitor ClinicalTrials.gov for updates on at least three registered trials evaluating injectable biologics for Achilles and patellar tendinopathy with target completion dates in 2027. The most probable near-term shift is not a single breakthrough therapy but a move toward staged, phenotype-matched treatment algorithms where the tendon's position on the pathology continuum determines which intervention is offered first.